GNW: Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a
potential first-in-class siRNA for the treatment of high cholesterol
* If approved, inclisiran will be the first and only small interfering RNA(siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia1
* Cardiovascular disease (CVD) claims 3.9 million lives annually in Europe2,and 80% of high-risk patients do not reach guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets despite the widespread use of statins3-5
* Inclisiran provides eff...